glp-1 safety concerns Do The Benefits of Drugs OutWeigh the Negatives? Scrolling through TikTok or Instagram

Diabetes Care 25 (5), 869875

The initial muscle loss seen with GLP-1 RA treatment as well as the ongoing replacement of muscle with fat with treatment cycles involving treatment interruptions can result in unfavorable changes in body composition in patients with obesity that can have profoundly negative repercussions, and can exacerbate obesity-related metabolic and health concerns 14,15,16

doi: 10.3390/ijms24076596

The trial looked at the safety and effectiveness of tirzepatide in two scenarios: Continuing to take tirzepatide at the maximum tolerated dose (10 or 15 milligrams [mg], depending on the patient) after initial treatment on that dose Lowering the dose to 5 mg after initial treatment to maintain weight loss